Χώρα: Ηνωμένες Πολιτείες
Γλώσσα: Αγγλικά
Πηγή: NLM (National Library of Medicine)
HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X)
Larken Laboratories, Inc.
HYOSCYAMINE SULFATE
HYOSCYAMINE SULFATE 0.375 mg
ORAL
PRESCRIPTION DRUG
This product may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries and diverticulitis. It can also be used to control gastric secretion, visceral spasm and hypermotility in cystitis, pylorospasm and associated abdominal cramps. Along with appropriate analgesics, this product is indicated in symptomatic relief of biliary and renal colic and as a drying agent in the relief of symptoms of acute rhinitis. This product is effective as adjunctive therapy in the treatment of peptic ulcer and irritable bowel syndrome, acute enterocolitis and other functional gastrointestinal disorders. Glaucoma, obstructive uropathy, obstructive diseases of the gastrointestinal tract, paralytic ileum, intestinal atony of elderly or debilitated patients, unstable cardiovascular status, severe ulcerative colitis, toxic megacolon, myasthenia gravis, and myocardial ischemia. This product is not recommended for use in children under twelve years of age.
OSCIMIN SR Tablets are supplied as green, capsule shaped tablets debossed “LL 255” on one side and plain on the opposite side. They are available in bottles of 100 tablets, NDC 68047-255-01. Store at controlled room temperature, 20°-25°C (68°-77°F), see USP Controlled Room Temperature. Dispense in tight, light-resistant containers as defined in USP/NF, with a child-resistant closure. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY . Distributed by: Larken Laboratories, Inc. Canton, MS 39046 Rev. 06/2017 500416-01
unapproved drug other
OSCIMIN- HYOSCYAMINE SULFATE TABLET, EXTENDED RELEASE LARKEN LABORATORIES, INC. _Disclaimer: This drug has not been found by FDA to be safe and effective, and this_ _labeling has not been approved by FDA. For further information about unapproved_ _drugs, click here._ ---------- OSCIMIN SR TABLETS DESCRIPTION Each sustained-release tablet for oral administration contains: Hyoscyamine Sulfate, USP …… 0.375 mg Hyoscyamine sulfate is one of the principal anticholinergic/ antispasmodic components of belladonna alkaloids. Hyoscyamine sulfate is Benzeneacetic acid, α-(hydroxymethyl)-, 8- methyl-8- azabicyclo[3.2.1]oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate. (C H NO ) • H SO • 2H O M.W. = 712.85 INACTIVE INGREDIENTS Inactive ingredients include: calcium phosphate dibasic, ethylcellulose, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, lactose monohydrate, magnesium stearate (veg.), microcrystalline cellulose, and stearic acid. CLINICAL PHARMACOLOGY Hyoscyamine has actions similar to those of atropine, but is more potent in both its central and peripheral effects. This product inhibits gastrointestinal propulsive motility and decreases gastric acid secretions. This product controls excessive pharyngeal, tracheal, and bronchial secretion. 17 23 3 2 2 4 2 Once absorbed, this product disappears rapidly from the blood and is distributed throughout the entire body. The majority of hyoscyamine sulfate is excreted in the urine unchanged within the first 12 hours and only traces of hyoscyamine sulfate are found in the breast milk. INDICATIONS AND USAGE This product may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries and diverticulitis. It can also be used to control gastric secretion, visceral spasm and hypermotility in cystitis, pylorospasm and associated abdominal cramps. Along with appropriate analgesics, this product is indicated in symptomatic relief of biliary and renal colic and as a drying agent in the relief of symptoms of acute rhinitis. Διαβάστε το πλήρες έγγραφο